INMB · INmune Bio Inc
United States · RS rating 30 · As of 2026-10-14
| Price | 1.60 USD |
|---|---|
| 1-day change | -4.8% |
| RS rating (overall / 1M / 3M / 12M) | 30 / 6 / 17 / 30 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 26 / 47 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +75.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +36.2% |
| Market cap (USD) | $36.7M |